New Age Alpha Advisors LLC Invests $1.78 Million in DaVita Inc. (NYSE:DVA)

New Age Alpha Advisors LLC bought a new stake in shares of DaVita Inc. (NYSE:DVA) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,915 shares of the company’s stock, valued at approximately $1,782,000.

Other hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after buying an additional 92,014 shares in the last quarter. Amundi boosted its position in shares of DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company’s stock valued at $68,726,000 after purchasing an additional 240,126 shares during the period. KBC Group NV boosted its position in shares of DaVita by 0.8% in the 4th quarter. KBC Group NV now owns 316,155 shares of the company’s stock valued at $47,281,000 after purchasing an additional 2,636 shares during the period. Nordea Investment Management AB increased its stake in DaVita by 4.9% in the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company’s stock worth $39,712,000 after purchasing an additional 12,339 shares in the last quarter. Finally, FMR LLC raised its holdings in DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DVA has been the topic of several research analyst reports. Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. Barclays raised their price objective on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Finally, StockNews.com lowered shares of DaVita from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, DaVita has a consensus rating of “Hold” and a consensus target price of $166.33.

DaVita Stock Down 1.5 %

Shares of DVA stock opened at $150.29 on Monday. The company has a market capitalization of $12.02 billion, a price-to-earnings ratio of 13.99, a PEG ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock’s 50 day simple moving average is $157.39 and its 200 day simple moving average is $157.55. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.